Arycs Technologies | $24,000,000 | (Mar 13, 2026)
Ezra(2) | $8,000,000 | (Mar 13, 2026)
Freestyle | $10,000,000 | (Mar 13, 2026)
Hemab Therapeutics
Denmark
- Copenhagen, Capital Region
- 22/02/2023
- Series B
- $135,000,000
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
- Industry Biotechnology Research
- Website https://hemab.com/
- LinkedIn https://www.linkedin.com/company/hemabaps/
Related People
Benny SorensenFounder
United States -
Cambridge, Massachusetts
Experienced patient centric Biotechnology Executive with demonstrated translational research, early- intermediate- and late stage clinical development experience. Strong entrepreneurial profile and successful track record of building lean high-performing R&D organizations. Excellent presentation and discussion skills. Extensive pharma-, biotech- and clinical academic high profile network.
Mantis Space | $10,000,000 | (Mar 13, 2026)
Monteris Medical | $28,000,000 | (Mar 13, 2026)
Gumloop | $50,000,000 | (Mar 13, 2026)
Combat Medical Ltd | $3,472,639 | (Mar 13, 2026)
Qurrent | $15,000,000 | (Mar 13, 2026)
Carefam | $14,500,000 | (Mar 13, 2026)
Option Circle | $3,000,000 | (Mar 12, 2026)
AgentMail (YC S25) | $6,000,000 | (Mar 12, 2026)